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Abstract 
Prostate cancer is one of the most common diagnosed cancers
in men and the waiting time has become an important issue not
only for clinical reasons, but also mostly for the psychological
implications on patients. The aim of our study was to review and
analyze the literature on waiting times for prostate cancer. In
February-March 2019 we performed a search for original peer-
reviewed papers in the electronic database PubMed (MEDLINE).
The key search terms were “prostate cancer AND waiting list”,
“prostate cancer AND waiting times”. We included in our narra-
tive review articles in Italian, English or French, published in
2009-2019 containing original data about the waiting times for
prostate cancer.  The literature search yielded 680 publications.
Finally, we identified 8 manuscripts eligible for the review. The
articles were published between 2010 and 2019; the studies
involved a minimum of 16 to a maximum of 95438 participants.
Studies have been conducted in 6 countries. The waiting times
from cancer suspicion to histopathological diagnosis and to treat-
ment had an important reduction in the last years, and this constant
decrease could lead to an increase of patients’ satisfaction.
Introduction
Prostate cancer is the second most common diagnosed cancer
in men, after the lung cancer.1 In the last years the number of men
who received a diagnosis of prostate cancer has increased: the
most important reason of this increase is the longer life expectan-
cy.2 In fact, the risk of developing prostate cancer increases with
age, and it is very rare in men younger than 50 years old.3 Surely
the second most important reason is the introduction and diffusion
of prostate-specific antigen (PSA) screening that led to a major
number of prostate tumors diagnosis, in particular those at the ini-
tial stage, compared to the advanced ones.2,4 The advent of PSA
testing and subsequent biopsy, led to an extraordinary change of
the epidemiology of this tumor:  now, up to 80% of diagnosed
prostate cancer are at an initial stage, posing small risk of morbid-
ity or mortality during patients’ lifetime.5,6 Moreover, as reported
in a recently published review, advances in the diagnosis and treat-
ment of prostate cancer have improved the ability to stratify
patients by risk and allowed clinicians to recommend therapy
based on cancer prognosis and patient preference.7
On the basis of several definitions in the literature, the WHO
definition of quality of care is “the extent to which health care
services provided to individuals and patient populations improve
desired health outcomes. In order to achieve this, health care must
be safe, effective, timely, efficient, equitable and people-
centred”.8,9
Patient satisfaction is an important measure of healthcare
quality and is correlated with important outcomes, such as superi-
or compliance, decreased utilization of medical services, less mal-
practice litigation and better prognosis.10
Waiting times are important for patient satisfaction and, in
many jurisdictions, the improvement in their reduction (especially
for cancer diagnosis and treatment) has become a priority.11 For
example, the Swedish Government had initiated a project to
reduce these waiting times by introducing national standardized
clinical pathways.12 Similarly, England and Wales started the so
called ‘two weeks wait’ programme, whilst in Denmark appeared
the national cancer pathways.13,14 Waiting times are relevant not
only for clinical reasons, but mostly for the psychological impli-
cations on patients: several studies conducted on other types of
cancer, in fact, have analyzed the relation between perceived wait-
ing times and patient satisfaction, although most of them focused
only on parts of the perceived waiting time, namely, family physi-
cian referral to specialist visit15 and diagnosis to treatment.16
In literature there are several reported experiences about how
long patients with suspected prostate cancer have to wait to
receive a biopsy or treatment, so the aim of our narrative review
was to analyze the studies published on this topic in order to have
an overview.
Significance for public health
The improvement in the reduction of the so-called “Waiting Times” for diagnosis and treatment of cancer has become a priority for several countries. In fact,
the “Waiting times” are relevant not only for clinical reasons, but mostly for the psychological implications on patients and for their satisfaction, which is
recognized as a key indicator of healthcare quality. Our narrative review focused on the waiting times for prostate cancer that is one of the most common
diagnosed cancers in men.
SYSTEMATIC REVIEWS AND META-ANALYSIS
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Methods
In February-March 2019 we performed a search for original
peer-reviewed papers in the electronic database PubMed (MED-
LINE). The key search terms were “prostate cancer AND waiting
list”, “prostate cancer AND waiting times”. The inclusion criteria
that we chose for our narrative review were: i) type of  article
(original articles, but also letters to the editor or short communica-
tions if containing original data); ii) date of publication between
2009 and 2019; iii)language (Italian, English or French); iv) avail-
ability of information about country, study period, source of the
data, number of participants, waiting times. Other interesting data
have also been reported.
Studies were selected in a 3-stage process. First we analyzed
the titles; then the abstracts from electronic searches. Finally we
collected and read the full manuscripts to select the eligible manu-
scripts according to the inclusion criteria. 
Results
The literature search yielded 680 publications. The titles of
these manuscripts were screened, resulting in 12 studies consid-
ered potentially eligible for abstract analysis (18 were duplicate, 76
were review, 249 were published before 2009, 312 were not in line
with the aim of our study, 13 were in other languages – 1 Chinese,
4 German, 5 Spanish, 1 Dutch, 1 Norwegian, 1 Hungarian). 
After abstract analysis 2 studies were further excluded because
not in line with the aim of our study, so the full texts analysis was
conducted on 10 manuscripts.  Finally, after this exclusion we
identified 8 manuscripts eligible for the review (2 excluded
because not in line with the aim of the study) (Figure 1).11,12,17-22
The articles were published between 2010 and 2019; the stud-
ies have been conducted from 1996 to 2015; they involved a min-
imum of 16 to a maximum of 95438 participants. Studies have
been conducted in Poland, Canada, Sweden, South Africa, United
Kingdom (UK) and France. 
The principal results of our review are shown in Table 1.
In some examined studies the waiting time for prostate cancer
has been divided in subgroups: from cancer suspicion to
histopathological confirmation, and from cancer diagnosis to the
start of treatment; other studies described the total waiting time
from cancer suspicion to treatment. 
Waiting time from cancer suspicion to treatment
Two studies reported this datum:17,22 although settled in differ-
ent countries we observed (after almost 10 years) a clear reduction
of this time from 247 days to 18.7 weeks (almost 130 days).
Waiting time from cancer suspicion to histopathological
confirmation
Four studies reported this datum:11,17,21,22 we observed a sub-
stantial stable trend during the years of this ‘time’ (53 days in
2003; 7.7 weeks in 2014-15). The results described by Singh and
by Mathews are not totally comparable. 
Waiting time from cancer diagnosis to the start of
treatment
Seven studies reported this datum:12,17-22 also for this datum
we observed a net reduction of this ‘time’ from almost 1200-1400
days (referred to chemotherapy) or 200 days (referred to surgery or
radiotherapy) in 2002 to 8.7 weeks in 2015 (almost 60 days).
Other findings
Two authors reported that high-risk patients had shorter wait-
ing times; one author17 reported a significantly higher waiting time
for patients who underwent radiotherapy, however this time has
diminished in the years as reported by Rastpour et al.19
One author observed no differences in survival on the basis of
the time of surgery (immediate, or after 4-6 months).20
Discussion 
The topic of “waiting times” has been investigated for several
cancers. Already in 2017, Labbè et al.  focused on lung cancer that
is the most frequently diagnosed cancer worldwide and the leading
cause of cancer-related mortality. In their study they affirmed that
reducing wait times should be a goal, because shorter waits might
influence important variables such as quality of life, cost of care,
access to therapies.23
Our study was focused on waiting times for prostate cancer
and the analysis of the literature highlighted a reduction of these
times during the years.  However, as reported by Robertson et al.,
men with prostate cancer had substantially longer waiting times
than patients with other kinds of cancer.12
Some limitations should be considered: first of all, our review
was not systematic, but it could be considered a narrative review
conducted on a single database. Moreover, the literature is limited
to some countries (specifically six countries), so it is difficult to
have a complete overview of this topic able to represent the world-
wide situation. Substantial differences among countries are actual-
ly impossible to define.
Another weakness of our study is the not-total comparability of
the data retrieved by the analyzed articles. 
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Figure 1. Flow diagram for identifying studies included in our
non-systematic (narrative) review.
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Table 1. Selected characteristics of the studies included in the review.
Author,    Country       Study    Involved         Data            Participants       Age                         Waiting time         Waiting  time                      Waiting time                         Other
year                           period    centers        source                                     (years)                    from cancer          from cancer                        from cancer                          findings
                                                                                                                                                            suspicion to          suspicion to                        diagnosis to
                                                                                                                                                            treatment              histopathological               the start of 
                                                                                                                                                                                           confirmation                       treatment                                  
Osowiecka,    Poland         2014 -2015            5              Questionnaire                   123                     - median 65                         18.7 weeks (IQR            7.7 weeks (IQR                                 8.7 weeks (IQR                                    A significant  longer 
201917                                                                                                                                                             - range 53–87                      10.6–26.9 weeks)           4.0–16.1 weeks)                                4.6–14.1 weeks)                                  waiting time for 
                                                                                                                                                                                                                                                                                                                                                                                               patients who began
                                                                                                                                                                                                                                                                                                                                                                                             treatment with radiation
                                                                                                                                                                                                                                                                                                                                                                                               therapy (p < 0.001)
Rastpour,       Canada         2002-2012           n/r             Retrospective                 95438                   n/r                                          n/r                           n/r                                                        -    From diagnosis to                         -    Increasing trend in 
201819                                                                                             administrative                                                                                                                                                                                                          chemotherapy 1200/1400                   median waiting time per
                                                                                                        data                                                                                                                                                                                                                    days (in 2002) –                                  year for surgery 
                                                                                                                                                                                                                                                                                                                                   400 days (in 2012)                               (2.6 days)
                                                                                                                                                                                                                                                                                                                               -    From diagnosis to                         -    Decreasing trend
                                                                                                                                                                                                                                                                                                                                   radiotherapy or                                   in median waiting 
                                                                                                                                                                                                                                                                                                                                   surgery almost 200 days                    time per year for 
                                                                                                                                                                                                                                                                                                                                                                                                    radiotherapy (-2.8 days)
                                                                                                                                                                                                                                                                                                                                                                                               -    Decreasing trend in
                                                                                                                                                                                                                                                                                                                                                                                                    median waiting time per
                                                                                                                                                                                                                                                                                                                                                                                                    year for chemotherapy 
                                                                                                                                                                                                                                                                                                                                                                                                    (-84.0 days)
Robertson,    Sweden             2013                n/r            Data furnished                 1955                    n/r                                          n/r                          n/r                                                        172 days                                                 The median waiting time
201712                                                                                 by National Board                                                                                                                                                                                                                                                                  for men with
                                                                                                   of Health                                                                                                                                                                                                                                                                         high-risk prostate 
                                                                                                 and Welfare                                                                                                                                                                                                                                                                       cancer was 26 days
                                                                                                                                                                                                                                                                                                                                                                                               shorter than  for men
                                                                                                                                                                                                                                                                                                                                                                                               with intermediate-risk
                                                                                                                                                                                                                                                                                                                                                                                               prostate cancer
Singh,                South               2013                  1              Retrospective                   106                     - mean                                                                            100 days****                                     100 days****                                       -    Median period to receive 
201521              Africa                                                          folder review                (52 had                67.6 years                                                                       (****number of days                                                                                          biopsy after suspicion: 
                                                                                                                                      confirmed              - standard                                                                      a patient waited to receive                                                                                  55 days
                                                                                                                               adenocarcinoma)        deviation 7.51                                                                a histological diagnosis,                                                                                  -   Median period of histological 
                                                                                                                                                                                                                                                                 and for treatment                                                                                                 processing time: 36 days 
                                                                                                                                                                                                                                                                 options to be discussed 
                                                                                                                                                                                                                                                                 or instituted)
Mathews,       Canada                n/r                  n/r                Interviews                       16                      - <65 years (50%)                    n/r                             84.0 days (range 5-642)**              n/r                                                       n/r
201511                                                                                (conducted either                                           ->65 years old (50%)                                                  (**authors refer to 
                                                                                                  in-person                                                                                                                                           the time from the first 
                                                                                               or by phone)                                                                                                                                        visit to diagnosis)                         
Redaniel,          UK           1996 -2009          n/r                 Dataset                     17043                  -15-54 years (11.68%).            n/r                         n/r                                                          95 days                                          No differences were 
201320                                                                                furnished by                                            -55-64 years (51.86%)                                                                                                           (IQR 70-125 days)                      observed in the survival 
                                                                                     South West Public                                       - >65 years (36.46%)                                                                                                                                                                     among patients who
                                                                                                Health                                                                                                                                                                                                                                                             underwent surgery at
                                                                                          Observatory                                                                                                                                                                                                                                                       time 0-3 and at time 
                                                                                             (SWPHO)                                                                                                                                                                                                                                                          4-6 months
Pourcel,        France             2012               n/r         Medical records              4207                   - Mean 68.0 years            n/r                          n/r                                                     -   Mean 36.5 days (SD 26.5)         n/r
201318                                                                                                                                                    -SD 8.8                                                                                                                                      from pathologist 
                                                                                                                                                                                                                                                                                                                 diagnosis to treatment
                                                                                                                                                                                                                                                                                                                 proposal 
                                                                                                                                                                                                                                                                                                             -   Mean 45.2 days 
                                                                                                                                                                                                                                                                                                                 (SD 30.1 or 38) from 
                                                                                                                                                                                                                                                                                                                 proposal to the start 
                                                                                                                                                                                                                                                                                                                 of treatment (non surgical 
                                                                                                                                                                                                                                                                                                                 or surgical)                                  
Stevens,       Canada             2003                 1          Semi-structured                41                     - median 70                       247 days*                      53 days                                             127 days***                                      From diagnosis to start of RT, 
201022                                                                                  interview                                               - range 41-77                    (*from                          (Sub-intervals:                               (***from biopsy to first               intermediate and
                                                                                                                                                                                                          suspicion to the          - from suspicion to                     fraction of RT)                                 high-risk patients
                                                                                                                                                                                                          first fraction)               consultation with                                                                                   had shorter wait 
                                                                                                                                                                                                          of RT                             an urologist = 40 days                                                                          times compared to
                                                                                                                                                                                                                                                   - from consultation to                                                                             low-risk patients
                                                                                                                                                                                                                                                   biopsy = 26 days)                                                                                  (124 vs. 178 days; p = 0.041)
                                                                                                                                                                                                                                                                                                                                                                         70% of participants perceived a
                                                                                                                                                                                                                                                                                                                                                                         delay in their prostate cancer
                                                                                                                                                                                                                                                                                                                                                                         pathway
IQR, interquartile range; RT, radiotherapy; n/r, not reported; SD, standard deviation.
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As for the “waiting times from cancer suspicion to treatment”,
although we observed a clear reduction of this time during the
years, it should be specified that Stevens et al. in their article
specifically refer to radiotherapy, whilst Osowiecka et al. generi-
cally refer to all the available treatments. 
As for the “waiting times from cancer suspicion to histopatho-
logical confirmation” the only studies that reported comparable
data are those of Osowiecka and Stevens: in fact the results
described by Singh and by Mathews are quite different. In particu-
lar, Singh reported the number of days that a patient waited to
receive a histological diagnosis, and for treatment options to be
discussed or instituted; Mathews, instead, reported the time from
the first visit to diagnosis, but it is not clear if this visit is from a
general practitioner or a specialized doctor. 
As for the “waiting time from cancer diagnosis to the start of
treatment”, Osowiecka, Robertson, and Redaniel, Singh did not
specify the type of treatment; whilst Pourcel and Stevens focused
on surgical/non surgical treatment and on radiotherapy respective-
ly. Stevens et al. reported an interesting datum regarding patients
perception of waiting times: in their study 70% of participants per-
ceived their “waiting time” as a delay in their prostate cancer path-
way. 
Surely, as demonstrated in studies conducted on colorectal
cancer, shorter waiting times are correlated with higher levels of
patients’ satisfaction;24 however, in many cases, patients with
longer waiting times generally had less advanced disease and bet-
ter survival, so the typical delays are not of clinical significance.25
Wanis et al. confirmed these evidences reporting that, despite
longer median colon cancer treatment waiting times from diagno-
sis to surgery (exceeding 30 days or 2-3 months), no adverse
impact on survival has been observed.26
In our study, Redaniel et al. confirmed these evidences for
prostate cancer observing no differences in the survival among
patients who underwent surgery at time 0-3 and at time 4-6
months. In fact, among men with low-risk prostate carcinoma, a
treatment delay of several months does not appear to compromise
long-term oncologic results following definitive treatment.27 Also
considering only radiotherapy as treatment, the delay does not
affect outcomes in low-risk patients.28
The only reported side effect is that treatment delay between
biopsy and prostatectomy in patients with a high risk may result in
more extensive periprostatic tissue resection and may adversely
affect postoperative continence and erectile function.29
Conclusions
Concluding, prostate cancer is one of the life threatening and
most frequent case of disorders and a proper treatment and other
control strategies are fundamental to manage it.30 Our review,
although with some limitations due to the choice to use only one
biomedical database, demonstrated that the “Waiting time from
cancer suspicion to treatment”, the “ Waiting time from cancer sus-
picion to histopathological confirmation” and the “Waiting time
from cancer diagnosis to the start of treatment” are constantly
diminishing. Although not of clinical significance, this reduction
could be positively felt by patients, and could lead to an increase
of patients satisfaction, recognized as a key indicator of health care
quality, especially in oncology.31 Since a recent study has found a
negative association between diagnostic delay and patient satisfac-
tion in gynecologic cancer patients,32 it is therefore conceivable
that, also for prostate cancer, a delay and a longer waiting time
could lead to a lower satisfaction level.
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